TrialJournal of neurology2023

Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).

Francesco Saccà et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.